Star. the word has been cherished by jonnie for a long time, be it Star Scientific, his prior aviation company, Starwood Aviation, and the trademark Starpure and old trademark Starcure. jonnie even resides on a 29 acre estate on Starwood Lane. now there's a Starion, set up by former Star employees (a curious vagueness and mystery in who these employees are) who will license from Star and lease part of Star's space. in a few weeks, jonnie is handing the reigns to more qualified personnel to drive the pharmaceutical business, and yet, he will remain employed (another curious vagueness in responsibility). perhaps jonnie, entrepreneur, idea-man, 'genius', and son of a former philip morris employee, will be a possible lead for Starion.
mere speculation, of course.
From Schedule 14A:
Record Date; Outstanding Shares; Shares Entitled to Vote
"Our Board of Directors has fixed the close of business on October 30, 2013, as the record date, or “Record Date,” for determining the stockholders entitled to notice of, and to vote at, the Annual Meeting. On the Record Date, we had 169,122,155 shares of common stock issued and outstanding held by approximately 606 stockholders of record. We have no other class of voting securities outstanding."
7,126,000,000 people in the world.
606 shareholders presently in rcp.
7,125,999,394 people (give or take) will miss out on the profit (or loss) to come.
106 shareholders will sell as share price doubles.
400 more will sell off as price quadruples.
100 'original' shareholders will remain (as newbies buy in and out all the while) to realize even greater profits.
from the movie '300':
Persian: A thousand nations of the Persian empire descend upon you. Our arrows will blot out the sun!
Spartan: Then we will fight in the shade.
and it's drum who's franitically writing more than anyone. now THAT's funny. still scared at 1.28. regardless of his words and rebuttals, he knows there's much more to this company than current share price.
people are sheep - people are timid, and with few leaders, the masses follow others. if some sell, others will follow, spurring still others to follow. inversely, as the price rises, some will buy in, swaying others to buy in as well.
people are scared - lots of change happening this quarter. many (like myself) see the changes as positive. yet people are easily spooked and get nervous with change and the 'unknown'. being risk averse is not bad, however, those will reap fewer profits (and conversely, fewer losses if it be the case).
people are undisciplined - using anatabloc requires discipline in persistently taking the recommended dose at the suggested intervals. people forget, become lazy, or consume smaller doses to save money. the time release version will soon help this tremendously!
people are impatient - people want results and they want results immediately...even if the disorders they have took years, even decades to develop. we reside in an instant gratification society. i want what i want NOW! some benefits of anatabloc will take weeks, even months to realize.
people are frugal - the cost of abloc cause many to hesitate, even though health care will belittle the cost in hindsight. the cost is slowly dropping, though, with price decreases and increased pill quantity, and should continue with higher quantities manufactured in the future.
people are reluctant - people generally need to see a marketing message multiple times, often dozens of times, before they commit to trying a product. i advised a girl years ago (before anatabloc) to try a product for chronic allergies...she literally cried herself to sleep nightly...'i'll try ANYTHING'! no sale.
people are UNINFORMED - few recognize the name anatabloc presently. few understand anatabine and its benefits. few know about the clinicals, peer reviews, or have even heard of star (or rcp). only a small core of individuals are familiar. mullan, chapman, and the new team of directors WILL change this in time.
"I do not put you on ignore but read your posts any time I am down"
that said, you are clearly down constantly, as you evidently read ALL posts and respond to them often. your life need not be so depressing.
and my posts may be a lot of things...but not dross. that stung.
you're actually somewhat right for a change. anatabine was quite a find. it helps with so many disorders, they're seeking the most beneficial avenues to pursue. why settle for one niche when it aids in so many? ironically, you're headline seems to refer to yourself...'trying to find a purpose.' we all are, or at least should be, and you are apparently floundering. ask yourself what YOUR purpose is in life. you don't know? is this the pinnacle of your reason for being? bashing and belittling companies in order to gain by greed? let's be honest...you've burned through 47 years thus far. and to what avail? what do you have to show for your time? your posts speak louder than the answer you conjur up within. don't kid yourself. until you can clearly define your own purpose, a meaningful, lasting purpose that transcends your short span here and is other than about you, what authority have you in ridiculing the purpose of anyone or anything else?
there was surely an exclusive rights to sell deal made with gnc for some time...my guess, 2-4 years...anyone privy to typical exclusive rights terms with gnc? by that time, a time release version will be well out, more recognition received, and additional studies will be complete, with an actual drug ready or soon to be available. it will be prime time to branch out to cvs, walgreens, sam's, costco, etc. gnc has the upper hand at the moment with marketing and selling, if you will...and that's fine, for we need them. it's a win-win. but 'shortly', rcp will gain leverage just as the exclusivity runs its course and opens to others.
definitely. jonnie will remain to help manage the company. he undoubtedly wants mullan as well...it's in his best interest to further his company and boost share price. hiring mullan is like hiring the best 'ambassador' thus far...a leader in Alzheimer's research. he will be respected and listened to in places fred and isner would never get the time of day...though both admired in their own domains.
it will be virtually unanimous, no question...except for that one guy way in the back...there's always that one guy. it's what everyone wants...shareholders, new directors, new ceo and pres, even jw and pp.
mullan's plan? facial crème...facial serum? lowest priority. anatabloc? of course, especially in short-term, but mid-priority, imo.
he obviously wants the heavy hitting goods...a line of fda approved drugs treating a range of disorders. an incredible team with mullan, chapman, wright, and other new directors coming aboard. mullan will get the attention and respect he's due, chapman has contacts and experience in pharmaceutical channels, and curtis will 'fast-track' as quickly as possible.
Curtis. Will get it. Through.
Curtis Wright, M.D., MPH, 63, has served as Senior Vice-President, Medical/Clinical Director of our pharmaceutical subsidiary, Rock Creek Pharmaceuticals, Inc. since February 2008. Dr. Wright previously served as Vice President of Clinical and Regulatory Affairs for Adolor Corporation from 1997 to 1998, and Executive Director, Medical Affairs and subsequently Executive Director of Risk Assessment for Purdue Pharma from 1998 to 2004. Immediately prior to joining Rock Creek Pharmaceuticals, Inc., Dr. Wright served as Executive Vice President for Risk Management and Regulatory Affairs at Javelin Pharmaceuticals, Inc., Cambridge, Massachusetts from 2004 to 2008. Dr. Wrights career at the FDA, from 1989 through October 1997, included multiple senior scientific positions in the Center for Drug Evaluation and Research, including Deputy Director, and subsequently, Acting Director of his division. Dr. Wright received his medical degree, with distinction, from George Washington University and received a masters degree in Public Health from the John Hopkins University.
just a few takes from the filing...
"Mr. Williams will continue as a non-executive employee of the Company for one year...Mr. Williams has further indicated that, following the one-year period described above, he is willing to serve as a consultant to the Company to provide continued assistance with patent prosecutions and new product development. The terms of any such arrangement would be determined by Mr. Williams and the New Board."
GOOD, jonnie stays!
"Mr. Williams is expected to perform such duties as may be prescribed by Dr. Mullan or Dr. Chapman, which may include efforts in connection with product development and the continued expansion of the Company’s patent portfolio."
"Our Existing Board believes that the Company will benefit from the reputations of Drs. Mullan and Chapman, particularly as related to potential business partners and collaborations. Drs. Mullan and Chapman are well recognized in the pharmaceutical industry, and our Board of Directors believes we will benefit from their respective industry contacts."
"we believe that the government and internal investigations that the Company has been subject to are nearing completion. See our Quarterly Report on Form 10-Q for the period ended September 30, 2013, filed November 12, 2013. Our Existing Board considered that, given the status of such investigations, it was appropriate to consider the corporate transition matters at this time."
third quarter REVENUES decreased by 10%, partly due to the increased 300 count bottles and partly due to gnc assuming a greater stake in the selling and profit-taking, while 'general and administrative SELLING' decreased by 44% in the same quarter. that's a sizeable decrease in selling expense as gnc bears a larger marketing presence in our stead.
it cannot be a LEVEL playing field, pablo. society would have to be rational, just, and discerning, holding integrity at a premium. what a deranged and unrecognizable world THAT would be. : \
from 99.5 Blakefm country radio:
'Thomas Rhett is Selling Out Shows'
"Well – it’s almost time! The 4th Annual Anatabloc Taste of Country Christmas Tour driven by Ford is this Saturday, Nov. 16th! Thomas Rhett will take the Suddenlink Stage at Wild West! Here’s some things you need to know…Thomas Rhett kicked this tour off last weekend in Abilene, TX, Wichita Falls, TX and Lawton, OK – and each show SOLD OUT! Of course this tour is predicted to sell out with Thomas Rhett’s latest single “It Goes Like This” being #2 on Billboard’s Hot Country Song and his album he released Oct 29th, It Goes Like This, is also #2 on Billboard’s Top Country Album. Not to mention Thomas Rhett has recently made appearances on NBC’s The Tonight Show with Jay Leno, the nationally syndicated Queen Latifah Show and tonight (Nov 13) he will be on NBC’s Late Night with Jimmy Fallon (make sure you set your DVR’s)."
Context: Hashimoto’s thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto’s thyroiditis.
Objective: The effects of anatabine in patients with Hashimoto’s thyroiditis.
Design, Setting, Patients, and Intervention: Double-blind, randomized, placebo-controlled multi-site study. A total of 146 patients (70 treated with anatabine, and 76 placebo) completed the study. Approximately 50% of patients in each group were on levothyroxine medication. Anatabine lozenges (9–24 mg/day) or placebo, each containing vitamins A and D3, were administered orally 3 times a day for three months.
Main Outcome Measures: Assessment of serum thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). Safety was assessed though adverse events (AEs), clinical laboratory evaluations, and vital sign measurements.
Results: Anatabine treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those on placebo (p=0.027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb. Mean (±SD) TgAb values decreased by 46.2 (±101.1) and 3.9 (±83.9) WHO units for the anatabine and placebo groups, respectively. Significantly more patients had a 20% drop in TgAb in the anatabine than placebo group (p=0.023). Overall the anatabine supplement was safe and well tolerated, although significantly (p
"Early Release articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance, on a weekly basis, before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Early Release manuscripts and the final, typeset articles. The manuscripts remain listed on the Early Release page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Early Release page."